KRTX Overview

Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by unmet medical needs. Its product candidate, KarXT is an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues.

Wall Street analysts forecast KRTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRTX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Karuna Therapeutics, Inc. revenue for the last quarter amounts to NaN USD, decreased % YoY.

Karuna Therapeutics, Inc.. EPS for the last quarter amounts to USD, decreased % YoY.

Karuna Therapeutics, Inc. (KRTX) has 210 emplpoyees as of February 10 2026.

Today KRTX has the market capitalization of 12.60B USD.